Shares of Diabetes Stocks Are Trading Lower Following Successful Obesity Data From Lilly.

BenzingaApr 17 11:24 ET

Express News | Diabetes Device Makers' Shares Down After Eli Lilly's Pill Leads to Weight Loss in Late-Stage Trial

ReutersApr 17 09:42 ET

Barclays Names Most and Least Affected Healthcare Companies From Tariffs

Seeking AlphaApr 16 13:04 ET

RBC Capital Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $45

Moomoo NewsApr 16 02:32 ET · Ratings

RBC Cuts Price Target on Tandem Diabetes Care to $45 From $55, Keeps Outperform Rating

MT NewswiresApr 15 06:43 ET · Ratings

Forecasting The Future: 9 Analyst Projections For Tandem Diabetes Care

BenzingaApr 10 08:00 ET

Tandem Diabetes Care Analyst Ratings

BenzingaApr 10 07:19 ET · Ratings

Mizuho Securities Initiates Tandem Diabetes Care(TNDM.US) With Hold Rating, Announces Target Price $20

Moomoo NewsApr 10 02:40 ET · Ratings

Hold Rating for Tandem Diabetes Care Amid Competitive and Macroeconomic Challenges

TipRanksApr 9 16:45 ET · Ratings

Tandem Diabetes Care (NASDAQ:TNDM Investor Three-year Losses Grow to 86% as the Stock Sheds US$154m This Past Week

Simply Wall StApr 8 12:53 ET

Express News | Tandem Diabetes Care Inc : Citigroup Cuts Target Price to $20 From $24

ReutersApr 7 07:25 ET

Press Release: Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025

Dow JonesApr 3 16:15 ET

Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025

Tandem Diabetes Care Apr 3 00:00 ET

Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $60

Moomoo NewsMar 25 00:31 ET · Ratings

Tandem Diabetes Announces NEJM Publication Of Control-IQ+ Trial For Type 2 Diabetes, Showing Significant A1C Reductions Of 0.9% Overall And 2.3% For A1C ≥9%, Meeting Primary Endpoint

BenzingaMar 19 10:02 ET

TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $27

Moomoo NewsMar 19 02:31 ET · Ratings

Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes With Control-IQ+ AID Technology in Type 2 Diabetes

Tandem Diabetes Care Mar 19 00:00 ET

Express News | Tandem Diabetes Care Inc : TD Cowen Cuts Target Price to $27 From $40

ReutersMar 18 23:56 ET

Express News | Tandem Diabetes Care Launches New Control-Iq+ Automated Insulin Delivery Technology in the United States

ReutersMar 18 16:05 ET

Barclays Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $53

Moomoo NewsMar 18 04:33 ET · Ratings